nach oben

Erschienen in:

01.07.2012 | Original article

Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer

Toxicity, tumour response and outcome

verfasst von: K. Vandecasteele, M.D., A. Makar, M.D., Ph.D., R. Van den Broecke, M.D., Ph.D., L. Delrue, M.D., H. Denys, M.D., Ph.D., K. Lambein, M.D., B. Lambert, M.D., Ph.D., M. van Eijkeren, M.D., Ph.D., P. Tummers, M.D., G. De Meerleer, M.D., Ph.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The goal of this work was to evaluate the feasibility and outcome of intensity-modulated arc therapy ± cisplatin (IMAT ± C) followed by hysterectomy for locally advanced cervical cancer.

Patients and methods

A total of 30 patients were included in the study. The primary tumour and PET-positive lymph node(s) received a simultaneous integrated boost. Four weeks after IMAT ± C treatment, response was evaluated. Resection consisted of hysterectomy with or without lymphadenectomy. Tumour response, acute and late radiation toxicity, postoperative morbidity and outcome were evaluated.

Results

All hysterectomy specimens were macroscopically tumour-free with negative resection margins; pathological complete response was 40%. In 2 patients, one resected lymph node was positive. There was no excess in postoperative morbidity. Apart from two grade 3 hematologic toxicities, no grade 3 or 4 acute radiation toxicity was observed. No grade 3, 1 grade 4 (4%) intestinal, and 4 grade 3 (14%) urinary late toxicities were observed. The 2-year local and regional control rates were 96% and 100%, respectively. The 2-year distant control rate was 92%. Actuarial 2-year progression free survival rate was 89%. Actuarial 1- and 2-year overall survival rates were 96% and 91%, while 3-year overall survival was 84%.

Conclusion

Surgery after IMAT ± C is feasible with low postoperative morbidity and radiation toxicity. Local, regional, distant control and survival rates are promising.

Brocker K, Alt C, Eichbaum M et al (2011) Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT. Strahlenther Onkol 187:611–618PubMedCrossRef

Carcopino X, Houvenaeghel G, Buttarelli M et al (2008) Equivalent survival in patients with advanced stage IB-II and III-IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy. Eur J Surg Oncol 34:569–575PubMedCrossRef

Chassagne D, Sismondi P, Horiot JC et al (1993) A glossary for reporting complications of treatment in gynecological cancers. Radiother Oncol 26:195–202PubMedCrossRef

Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRef

Cozzi L, Dinshaw KA, Shrivastava SK et al (2008) A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncol 89:180–191PubMedCrossRef

De Meerleer G, Vakaet L, Meersschout S et al (2004) Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60:777–787CrossRef

Duthoy W, De Gersem W, Vergote K et al (2004) Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer. Int J Radiat Oncol Biol Phys 60:794–806PubMedCrossRef

Ferrandina G, Margariti PA, Smaniotto D et al (2010) Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery. Gynecol Oncol 119:404–410PubMedCrossRef

Fonteyne V, De Neve W, Villeirs G et al (2007) Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol 84:156–163PubMedCrossRef

10.

Green J, Kirwan J, Tierney J et al (2005) Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev: CD002225

11.

Guerrero M, Li XA, Ma L et al (2005) Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations. Int J Radiat Oncol Biol Phys 62:933–939PubMedCrossRef

12.

Hasselle MD, Rose BS, Kochanski JD et al (2011) Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 80:1436–1445PubMedCrossRef

13.

Keys HM, Bundy BN, Stehman FB et al (2003) Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 89:343–353PubMedCrossRef

14.

Kirwan JM, Symonds P, Green JA et al (2003) A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 68:217–226PubMedCrossRef

15.

Lammering G, De Ruysscher D, Baardwijk A van et al (2010) The use of FDG-PET to target tumors by radiotherapy. Strahlenther Onkol 186:471–481PubMedCrossRef

16.

Loizzi V, Cormio G, Loverro G et al (2003) Chemoradiation: a new approach for the treatment of cervical cancer. Int J Gynecol Cancer 13:580–586PubMedCrossRef

17.

Lukka H, Hirte H, Fyles A et al (2002) Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer—a meta-analysis. Clin Oncol (R Coll Radiol) 14:203–212

18.

Marnitz S, Stromberger C, Kawgan-Kagan M et al (2010) Helical tomotherapy in cervical cancer patients: simultaneous integrated boost concept: technique and acute toxicity. Strahlenther Onkol 186:572–579PubMedCrossRef

19.

Morice P, Uzan C, Zafrani Y et al (2007) The role of surgery after chemoradiation therapy and brachytherapy for stage IB2/II cervical cancer. Gynecol Oncol 107:S122–124PubMedCrossRef

20.

Niibe Y, Hayakawa K, Kanai T et al (2006) Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose. Eur J Gynaecol Oncol 27:47–49PubMed

21.

Pasler M, Wirtz H, Lutterbach J (2011) Impact of gantry rotation time on plan quality and dosimetric verification – volumetric modulated arc therapy (VMAT) vs. intensity modulated radiotherapy (IMRT). Strahlenther Onkol 187:812–819PubMedCrossRef

22.

Perez CA, Breaux S, Madoc-Jones H et al (1983) Radiation therapy alone in the treatment of carcinoma of uterine cervix. I. Analysis of tumor recurrence. Cancer 51:1393–1402PubMedCrossRef

23.

Perez CA, Grigsby PW, Chao KS et al (1998) Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 41:307–317PubMedCrossRef

24.

Potter R, Dimopoulos J, Georg P et al (2007) Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 83:148–155PubMedCrossRef

25.

Small W, Jr, Mell LK, Anderson P et al (2008) Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 71:428–434PubMedCrossRef

26.

Vandecasteele K, De Neve W, De Gersem W et al (2009) Intensity-modulated arc therapy with simultaneous ntegrated boost in the treatment of primary irresectable cervical cancer. Strahlenther Onkol 185:799–807PubMedCrossRef

27.

Yeoh EE, Fraser RJ, McGowan RE et al (2003) Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 55:943–955PubMedCrossRef

Titel: Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer
Toxicity, tumour response and outcome
verfasst von: K. Vandecasteele, M.D.
A. Makar, M.D., Ph.D.
R. Van den Broecke, M.D., Ph.D.
L. Delrue, M.D.
H. Denys, M.D., Ph.D.
K. Lambein, M.D.
B. Lambert, M.D., Ph.D.
M. van Eijkeren, M.D., Ph.D.
P. Tummers, M.D.
G. De Meerleer, M.D., Ph.D.
Publikationsdatum: 01.07.2012
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 7/2012
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-012-0097-0

Springer Medizin

Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer

Toxicity, tumour response and outcome